You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

8 Results
Drug
Other Name(s): Tasigna®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gefitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niLOtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gilteritinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022
Drug
Other Name(s): Xospata®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2023
Drug
Other Name(s): Zejula
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Drug
Other Name(s): Iressa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025